Source comparison
PT-141 for Erectile Dysfunction Research: PDE5 Inhibitor vs Melanocortin Agonist Comparison
The table below compares mechanism, onset, contraindications, and research use cases for PT-141 versus sildenafil (the prototypical PDE5 inhibitor). Understanding these differences clarifies when each compound is appropriate for specific experimental models. M
This comparison does not assign a generated winner or score.
- The table below compares mechanism, onset, contraindications, and research use cases for PT-141 versus sildenafil (the prototypical PDE5 inhibitor). Understanding these differences clarifies when each compound is appropriate for specific experimental models.
- Mechanism of Action
- MC3R/MC4R agonism in hypothalamus and brainstem. Activates central desire pathways
- PDE5 inhibition in corpus cavernosum. Increases cGMP, dilates penile arteries
- PDE5 inhibition (longer half-life). Same mechanism as sildenafil
- PT-141 is the only option that bypasses peripheral vascular requirements entirely
- Onset of Action
- 45–60 minutes subcutaneous; peak plasma 60–90 minutes
- 30–60 minutes oral; peak plasma 60 minutes
- 30–45 minutes oral; peak plasma 2 hours
- Subcutaneous administration delays PT-141 slightly but offers dose precision
- Duration
- 6–8 hours measurable effect
- 4–6 hours
- 24–36 hours
- Tadalafil's extended window suits spontaneous use; PT-141 suits scheduled research protocols
- Cardiovascular Contraindications
- Safe in nitrate users, no hypotensive risk
- Absolute contraindication with nitrates (risk of severe hypotension)
- Same as sildenafil
- PT-141 is the only melanocortin agonist safe for cardiovascular compromise populations
- Efficacy in Spinal Cord Injury
- Effective. Central mechanism intact
- Limited. Requires intact peripheral nerves
- Limited. Same as sildenafil
- PT-141 demonstrated 58% response rate in SCI populations where PDE5 inhibitors failed
- Primary Adverse Event
- Nausea (29–47%), transient BP elevation
- Headache (16%), flushing (10%)
- Headache (11%), back pain (6%)
- Nausea limits PT-141 tolerability but resolves with repeated dosing